Current treatment status-Undergoing active treatment-No response - Page 2 of 17 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Posted by on Nov 22, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...

Read More

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Posted by on Nov 2, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising responses in these patients.  Some...

Read More

Blinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia

Blinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia

Posted by on Oct 30, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the use of blinatumomab Blincyto; B) or inotuzumab ozogamicin (Besponsa; IO) as a bridge to stem cell transplant for patients with relapsed or refractory (unresponsive) B-cell acute lymphocytic leukemia (B-ALL).  This study concluded that both treatments are safe and effective as a...

Read More

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Posted by on Sep 24, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma. This study concluded that this combination was safe and effective in the long-term in these patients.   Some background...

Read More

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Posted by on Sep 24, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma.  This study concluded that this combination was safe and effective in the long-term in these...

Read More

Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?

Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?

Posted by on Sep 8, 2020 in Prostate cancer | 0 comments

In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel  (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...

Read More

Looking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination

Looking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to assess the effectiveness of atezolizumab (Tecentriq) in combination with cabozantinib (Cabometyx) versus docetaxel (Taxotere) in patients with metastatic non-small cell lung cancer (NSCLC) which has previously been treated with immunotherapy and platinum-based chemotherapy....

Read More

MTX-HOPE chemotherapy for patients over 70 with relapsed non-Hodgkin’s lymphoma

MTX-HOPE chemotherapy for patients over 70 with relapsed non-Hodgkin’s lymphoma

Posted by on Jun 27, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, etoposide) to treat patients over 70 with non-Hodgkin’s lymphoma (NHL) which had returned after previous treatments. It found that MTX-HOPE was an effective and safe treatment for these patients. Some background NHL is a group of cancers of the...

Read More